Capecitabine (CAP) is widely used in cancer treatment for its oral convenience and tumor targeting.
However, its effectiveness in hepatocellular carcinoma (HCC) is suboptimal, possibly due to metabolic enzyme expression differences.
This study aims to analyze these enzymes' expression differences and explore their correlation with clinical pathological factors, to inform personalized CAP treatment.
